{"filings":[{"id":1259358,"accession_number":"0001104659-26-077556","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2026-06-25T12:30:49+00:00","items":["5.02","9.01"],"status":"ready","headline":"SELLAS amends CEO Stergiou's COC severance to lump sum; revises Burns, Cicic agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Stergiou's change-in-control severance: lump sum of 24 months base salary plus 1.5x target bonus, full equity vesting, 18-month COBRA.","Non-COC severance for CFO Burns and SVP Cicic: 9 months base salary, pro-rata target bonus, up to 9 months COBRA reimbursement.","COC severance for Burns and Cicic: lump sum of 15 months base salary plus target bonus, 18-month COBRA, immediate full equity vesting.","All three agreements were approved by the board on June 24, 2026, after compensation committee review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1139324,"accession_number":"0001104659-26-075775","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2026-06-18T20:30:36+00:00","items":["5.07"],"status":"ready","headline":"SELLAS stockholders approve 20M share equity plan increase, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Robert Van Nostrand and Jane Wasman re-elected; Van Nostrand 66.5M for, Wasman 65.9M for.","Ratification of Baker Tilly US as independent auditor for FY2026 approved with 112.1M votes for.","Amendment to 2023 Equity Plan increasing authorized shares by 20M approved: 42.9M for, 27.3M against.","Non-binding advisory say-on-pay resolution passed: 52.9M for, 15.9M against.","Adjournment proposal approved with 90.6M for, 22.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788157,"accession_number":"0001104659-26-069251","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2026-06-02T12:30:40+00:00","items":["8.01","9.01"],"status":"ready","headline":"SELLAS Life Sciences raised $28.7M from warrant exercises in Apr-May 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received approximately $28.7 million in proceeds from warrant exercises during April and May 2026.","Cash and cash equivalents were $107.1 million as of March 31, 2026; now increased by warrant proceeds.","Common shares outstanding as of June 2, 2026: 196,632,574.","No other material events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40331,"accession_number":"0001390478-26-000009","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2026-05-12T20:07:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS reports 78 events in REGAL AML trial; Q1 net loss $8.4M, cash $107.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["78 events (deaths) occurred in pivotal Phase 3 REGAL trial of GPS in AML as of May 11; final analysis triggered at 80th event.","Cash and cash equivalents $107.1M at March 31, 2026; additional $7.5M from warrant exercises received in Q2 2026.","Net loss $8.4M for Q1 2026 ($0.05 per share) vs $5.8M loss ($0.07 per share) in Q1 2025.","Phase 2 trial of SLS009 in first-line AML dosing patients; topline data expected in Q4 2026.","R&D expenses $5.1M (up from $3.2M); G&A $4.1M (up from $2.9M) driven by BLA preparation and professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103509,"accession_number":"0001390478-26-000004","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS reports FY2025 net loss $26.9M ($0.25/shr); cash $71.8M; Phase 3 REGAL AML trial approaching final analysis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $26.9M ($0.25/shr) vs $30.9M ($0.50/shr) in FY2024; cash $71.8M at Dec 31, 2025.","Received additional $42.6M from warrant exercises in Q1 2026, strengthening balance sheet.","Phase 3 REGAL trial of GPS in AML nearing final analysis at 80 events; 72 events as of Dec 26, 2025.","Phase 2 SLS009 in r/r AML showed 46% ORR; expansion into newly diagnosed AML underway, first patient dosed.","European collaboration with IMPACT-AML to study SLS009 in ~40 newly diagnosed AML patients; enrollment expected Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103508,"accession_number":"0001104659-26-026384","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SELLAS Life Sciences receives additional $16.1M from warrant exercises, total $42.6M since Dec 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Additional $16.1M in proceeds from warrant exercises since January 8, 2026.","Total warrant exercise proceeds since Dec 31, 2025: approximately $42.6M.","Shares outstanding as of March 11, 2026: 179,536,724.","Previously reported $26.5M in proceeds as of January 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103507,"accession_number":"0001104659-26-001957","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"SELLAS Life Sciences estimates $71.8M cash at Dec 31, 2025; $26.5M from warrant exercises post-quarter","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Cash and cash equivalents estimate of $71.8M as of Dec 31, 2025 (unaudited, preliminary).","Received ~$26.5M in proceeds from common stock warrant exercises subsequent to year-end.","As of Jan 7, 2026, shares outstanding total 170,282,026.","No other operational or financial results disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119764,"accession_number":"0001390478-25-000021","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Q3 net loss $6.8M ($0.06/sh); cash $44.3M plus $29.1M warrant proceeds in Oct","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.8M ($0.06 diluted EPS) vs $7.1M ($0.10) a year ago; nine-month loss $19.2M ($0.20).","Cash and equivalents $44.3M at Sep 30, 2025; additional $29.1M net from warrant exercises in October.","Phase 3 REGAL trial of GPS in AML CR2 final analysis expected by year-end 2025 (80 events).","Phase 2 SLS009 in R/R AML data accepted for ASH 2025; trial in first-line AML to start Q1 2026.","R&D expense $4.2M (down 5% YoY); G&A expense $2.9M (down 3% YoY)."],"consensus_eps_estimate":-0.0667,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119763,"accession_number":"0001104659-25-102345","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SELLAS receives $31M from warrant exercise; issues new warrants at $2 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrants for up to 22,363,714 shares exercised immediately for $31M gross proceeds.","New registered warrants issued for 22,363,714 shares at $2.00, exercisable immediately for five years.","Financial advisors A.G.P. and Maxim Group receive 5.75% of gross proceeds fee plus up to $60K legal reimbursement.","Company restricted for 75 days from issuing equity or filing registration statements; 12-month ban on variable-rate transactions.","Virtual R&D Day on AML scheduled for October 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119762,"accession_number":"0001104659-25-096643","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SELLAS extends NYC office sublease by one year to Sept 2027 with no rent change","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sublease at Times Square Tower extended to September 30, 2027, from September 30, 2026.","Annual rent under the sublease remains unchanged.","Sublandlord is Times Square Tower Associates LLC (successor-in-interest).","No other material terms of the sublease were modified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136330,"accession_number":"0001104659-25-089272","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"SELLAS raises $23.6M via warrant exercise; issues new 5.5-yr warrants at $1.88 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holder cash exercises 19,685,040 shares at $1.20, yielding $23.6M gross proceeds.","In exchange, company issues new unregistered warrants to buy same number of shares at $1.88 (closing price Sep 10).","New warrants exercisable immediately, expire 5.5 years from issuance; resale registration statement to be filed within 30 days.","Company pays aggregate fee of 6.5% of gross proceeds to A.G.P. and Maxim Group as financial advisors.","90-day lock-up on share issuance and 12-month ban on variable-rate transactions included in inducement agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136329,"accession_number":"0001390478-25-000017","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Q2 net loss $0.07/sh; GPS Phase 3 IDMC positive; SLS009 meets endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IDMC recommends continuing pivotal Phase 3 REGAL trial of GPS in AML without modification; final analysis by year-end 2025.","Phase 2 SLS009 in r/r AML met all primary endpoints: 44% ORR in AML-MRC; median OS 8.9 months vs 2.4 month historical benchmark.","FDA recommends advancing SLS009 into first-line AML trial; 80-patient enrollment expected by Q1 2026.","Q2 2025 net loss $6.6M ($0.07/sh) vs $7.5M ($0.13/sh) in Q2 2024.","Cash $25.3M at June 30, 2025; additional $4.0M from warrant exercises in July 2025."],"consensus_eps_estimate":-0.0832,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153451,"accession_number":"0001104659-25-060704","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SELLAS annual meeting results: directors re-elected, ESPP amendment approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Class III directors Stergiou (36.4M for) and Varian (36.7M for); broker non-votes 17.8M.","Ratified Baker Tilly as auditor for FY2025: 56.9M for, 3.4M against, 1.0M abstain.","Approved ESPP amendment increasing shares by 800,000: 28.8M for, 14.0M against.","Non-binding advisory vote on executive compensation passed: 29.6M for, 12.8M against.","Recommended annual frequency for future say-on-pay votes (34.8M for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153450,"accession_number":"0001104659-25-057308","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"SELLAS appoints Baker Tilly as new auditor after Moss Adams merger","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Moss Adams merged into Baker Tilly US, LLP; auditors resigned June 3, 2025.","Audit committee approved Baker Tilly as successor independent auditor for FY2025.","No disagreements or reportable events occurred in prior fiscal years or interim.","Moss Adams' reports on 2024/2023 financials included going-concern explanatory paragraph."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153449,"accession_number":"0001390478-25-000009","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Q1 net loss $5.8M; cash $28.4M; reports positive OS in Phase 2 SLS009 AML trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.8M ($0.07 per share) for Q1 2025 vs $9.6M ($0.21) in Q1 2024.","Cash and cash equivalents $28.4M as of March 31, 2025; plus $4.0M from warrant exercises in April 2025.","Phase 2 SLS009 in r/r AML: mOS 8.9 mo (AML-MRC) and 8.8 mo (venetoclax-resistant), beating historic 2.5 mo.","Phase 3 REGAL (GPS) interim analysis supports continuation; final analysis expected 2025.","Closed $25M registered direct offering in Jan 2025; net proceeds for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172196,"accession_number":"0001390478-25-000004","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS reports FY2024 net loss $30.9M; Phase 3 REGAL trial interim analysis positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.9M ($0.50/share) vs $37.3M ($1.34) in FY2023; R&D expenses down to $19.1M.","Cash $13.9M at Dec 31, 2024; raised $25M in January 2025 registered direct offering.","Positive interim analysis for Phase 3 REGAL trial (GPS in AML); final analysis expected upon 80 events in 2025.","Phase 2 SLS009 in r/r AML: 56% ORR in AML-MRC cohorts; median OS >7.7 months vs historic ~2.5 months.","Received multiple regulatory designations: three FDA RPDD, one Fast Track, two EMA ODD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172195,"accession_number":"0001104659-25-007049","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SELLAS Life Sciences raises $25M in registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19,685,040 shares (or pre-funded warrants) plus 19,685,040 common warrants at $1.27 combined price.","Warrants exercisable at $1.20 per share, expire 5 years from issuance.","Gross proceeds ~$25M; net proceeds for working capital and general corporate purposes.","Offering priced at-the-market under Nasdaq rules; expected to close Jan 29, 2025.","Single healthcare-focused institutional investor; A.G.P. and Maxim as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172194,"accession_number":"0001104659-25-005648","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SELLAS announces positive interim analysis for Phase 3 REGAL trial of GPS in AML; IDMC recommends continuation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommended continuation of Phase 3 REGAL trial after interim analysis triggered by 60 deaths; no safety concerns.","Blinded data: fewer than 50% of patients deceased after median follow-up of 13.5 months; pooled median survival >13.5 months vs ~6 months historical.","Blinded immune response: 80% of GPS patients showed GPS-specific T-cell response, exceeding prior Phase 2 result of 64%.","Next final analysis planned at 80 events, expected in 2025; company preparing BLA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172193,"accession_number":"0001104659-25-004107","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SELLAS Life Sciences amends severance agreements for two officers to 15 months base salary upon change of control","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Board approved amendments to change-in-control severance agreements for SVP/Chief Development Officer Dragan Cicic and SVP/CFO John Burns.","Amendments provide for severance of 15 months of then-current base salary upon termination in connection with a change of control.","Original agreements were dated December 14, 2021; other provisions remain unchanged.","Full text of amendments to be filed in next periodic report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189172,"accession_number":"0001104659-24-127231","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SELLAS triggers interim analysis in Phase 3 REGAL trial of GPS in AML; IDMC meeting in Jan 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-specified threshold of 60 deaths reached, triggering IDMC interim analysis.","IDMC to review efficacy, futility, and safety data from the Phase 3 REGAL trial in January 2025.","GPS is a potential new treatment for acute myeloid leukemia (AML).","Company hosted a webcast on December 10, 2024, to discuss the milestone and possible outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189171,"accession_number":"0001390478-24-000022","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Q3 net loss narrows to $7.1M; Phase 3 AML interim analysis on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $7.1M ($0.10/sh) vs $9.3M ($0.33/sh) in Q3 2023; cash $21M.","Phase 3 REGAL (GPS) in AML: interim analysis of 60 events on track for Q4 2024.","FDA granted Rare Pediatric Disease Designation (RPDD) to GPS for pediatric AML.","SLS009 Phase 2a data in r/r AML to be presented at ASH Dec 8; 31% overall response.","R&D expenses $4.4M (-24% YoY); G&A expenses $3.0M (-14% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189170,"accession_number":"0001104659-24-106261","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SELLAS extends NY office sublease by one year to Sept 2026; rent unchanged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sublease expiration moved from Sept 30, 2025 to Sept 30, 2026.","Annual rent remains unchanged.","Premises at 7 Times Square, 25th floor; no other terms modified.","Counterparties: SELLAS as subtenant, Times Square Tower Associates as sublandlord."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205660,"accession_number":"0001390478-24-000016","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Life Sciences Q2 2024 net loss $7.5M; cash $9.1M; $21M capital raise; IDMC supports REGAL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.5M ($0.13/share) vs $8.8M ($0.31/share) in Q2 2023; R&D expenses $5.2M.","Cash $9.1M at June 30; subsequent $21M gross proceeds from premium-priced registered direct offering.","IDMC recommends continue Phase 3 REGAL (GPS) in AML without modifications; interim analysis expected by Q4 2024.","Phase 2a SLS009 in r/r AML: ORR 33% (60mg QW), 50% (30mg BIW), 100% in ASXL1 mutant cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205659,"accession_number":"0001104659-24-084952","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SELLAS Life Sciences raises $21M in registered direct offering at premium to market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$21M from sale of 15,849,056 units (share or pre-funded warrant + warrant) at $1.325/unit.","Warrants exercisable for 15,849,056 shares at $1.20, immediately exercisable, five-year term.","Maxim Group acted as sole placement agent; offering priced at premium to market reflecting investor demand.","Offering closed on August 1, 2024, under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222592,"accession_number":"0001104659-24-073957","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SELLAS Life Sciences stockholders re-elect two Class II directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scheinberg and Kalin re-elected as Class II directors (8.6M/8.8M for; 18.7M broker non-votes).","Ratified Moss Adams LLP as FY2024 auditor: 27.8M for, 1.7M against, 0.5M abstain.","Advisory 'say-on-pay' passed: 6.0M for, 4.8M against, 0.6M abstain; 18.7M broker non-votes.","Quorum: 30.0M shares (51.95%) represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222591,"accession_number":"0001390478-24-000011","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Q1 net loss $9.6M; Phase 2 SLS009 100% response in ASXL1 AML; IDMC backs REGAL trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($0.21/share) vs $11.1M ($0.47/share) in Q1 2023.","Cash and equivalents $18.4M at March 31, 2024; R&D expense $5.1M, G&A $4.5M.","IDMC recommends continue Phase 3 REGAL (GPS in AML) without modification; next review June 2024 of all 127 patients.","SLS009 Phase 2: 62% anti-leukemic activity all doses, 67% at 30mg BIW; 100% ORR in ASXL1 mutation patients at 30mg BIW; cohort expanding.","Phase 3 REGAL enrollment completed; provisional patent filed for SLS009 in ASXL1-mutated AML."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242114,"accession_number":"0001390478-24-000005","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS FY2023 net loss $37.3M; SLS009 shows 50% response rate in r/r AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.3M ($1.34/sh) vs. $41.3M ($2.13/sh) in 2022; R&D expense $24.0M.","Cash at Dec 31, 2023: $2.5M; subsequent $9M (Jan) and $20M (Mar 2024) raised.","Phase 2a SLS009 in r/r AML: 50% response at 30mg BIW optimal dose; 100% in biomarker patients.","Phase 3 REGAL (GPS) enrollment completed; IDMC meeting late April; interim analysis possible in 1H2024.","Phase 1b/2 SLS009 in PTCL top-line data expected 1H2024; first DLBCL combo patient dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242113,"accession_number":"0001104659-24-040176","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SELLAS partner GenFleet doses first patient in Phase Ib/II combo trial of GFH009 + BRUKINSA for DLBCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GenFleet entered clinical trial collaboration with BeiGene for GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib).","First patient dosed in open-label, single-arm, multi-center Phase Ib/II trial for relapsed/refractory DLBCL in China.","Trial evaluates safety and efficacy of the combination therapy; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242112,"accession_number":"0001104659-24-035028","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SELLAS raises ~$20M in registered direct offering plus warrants priced at $1.535/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$20M from sale of 13,029,316 shares (or pre-funded warrants) at $1.535/share on Nasdaq.","Concurrent private placement of warrants to purchase up to 13,029,316 shares at $1.41, exercisable for 5.5 years.","Offering includes warrants exercisable immediately; closing expected March 19, 2024.","Net proceeds to fund R&D, working capital, and general corporate purposes.","A.G.P./Alliance Global Partners acting as sole placement agent with 7% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242111,"accession_number":"0001104659-24-032964","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SELLAS regains Nasdaq minimum bid price compliance effective March 11, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed compliance after closing bid price above $1.00 for 10 consecutive business days through March 8, 2024.","Company had been notified of non-compliance on February 14, 2024, and given a 180-day grace period until August 12, 2024.","Non-compliance matter is now closed; no further action required.","This removes a potential delisting risk for SELLAS common stock (SLS)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242110,"accession_number":"0001104659-24-032384","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"SELLAS terminates EVP General Counsel and SVP Chief Commercial Officer; reorganizes leadership","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barbara Wood (EVP, GC, Corp Secretary) terminated without cause, effective April 15, 2024.","Robert Francomano (SVP, Chief Commercial Officer) terminated without cause, effective March 31, 2024.","Company streamlines leadership, engages commercial consultant for partnerships; Stacy Yeung promoted to VP legal/compliance.","CEO reaffirms focus on Phase 3 REGAL interim analysis and SLS009 topline data in Q1/Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242109,"accession_number":"0001104659-24-030997","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SELLAS Life Sciences regains Nasdaq compliance for minimum market value rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on March 5, 2024 confirming compliance with Listing Rule 5550(b)(2).","Company maintained market value of common stock above $35M for 10 consecutive business days.","Previous non-compliance notice received on December 6, 2023; matter now closed.","Regains compliance before the June 3, 2024 deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242108,"accession_number":"0001104659-24-024898","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SELLAS receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified SELLAS on Feb 14, 2024 that common stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.","No immediate impact on listing or trading; stock continues trading under symbol SLS.","Company has 180 calendar days, until Aug 12, 2024, to regain compliance by closing bid price >=$1.00 for 10 consecutive business days.","If not compliant by Aug 12, may be eligible for additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to cure via reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242107,"accession_number":"0001104659-24-002295","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SELLAS Life Sciences prices $9.0M public offering of 12M shares and warrants at $0.75/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $9.0M from sale of 12M shares/common stock equivalents and 12M warrants at $0.75 per unit.","Warrants exercise price $0.75 per share, immediately exercisable, expire in five years.","A.G.P./Alliance Global Partners acting as sole placement agent; closing expected Jan 8, 2024.","Exercise price reduced to $0.75 on ~7.5M warrants from prior issuances; term extended to Jan 8, 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242106,"accession_number":"0001104659-24-000958","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"SELLAS Life Sciences terminates $50M ATM sales agreement with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutual termination of Controlled Equity Offering Sales Agreement dated April 16, 2021.","ATM program allowed up to $50M in common stock sales; prior termination, 1,294,814 shares sold for ~$10.5M net.","Related prospectus supplement filed in 2021 also terminated effective immediately.","Company may explore alternative financing options going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259517,"accession_number":"0001104659-23-128598","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SELLAS initiates arbitration against 3D Medicines over $13M milestone payments and GPS development in China","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Dispute over $13M development milestone payments due under 2020 license agreement for GPS in China region.","3D Medicines enrolled patients in Taiwan but failed to begin mainland China enrollment as expected in H2 2023.","SELLAS claims 3D Medicines failed to use commercially reasonable best efforts; arbitration filed at HKIAC under NY law.","Company cannot predict arbitration outcome or timing of any milestone payments or damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259516,"accession_number":"0001104659-23-125716","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SELLAS extends NYC office sublease term to Sept 2025; annual rent $635K from Jan 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment to Sublease extends term from Dec 30, 2024 to Sep 30, 2025.","Annual rent for Jan 2025–Sep 2025: $635,250 ($52,937.50/month); Dec 31, 2024 rent is $0.","Premises deemed 8,470 rentable sq ft; accepted in 'as is' condition; no landlord work.","Security deposit of $225,000 to be transferred to new sublandlord Times Square Tower Associates LLC.","Electricity to be paid based on metered consumption plus 3% administrative charge."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259515,"accession_number":"0001104659-23-124681","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SELLAS receives Nasdaq deficiency notice for market value below $35M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified SLS on Dec 6, 2023 that MV of common stock was below $35M for 30 consecutive business days.","Company has 180 calendar days, until June 3, 2024, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(C).","To regain compliance, market value must be at least $35M for 10 consecutive business days during the period.","Failure to comply by June 3, 2024 may lead to delisting, subject to appeal to a Nasdaq Hearings Panel.","SLS stock remains listed on Nasdaq Capital Market under symbol SLS at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259514,"accession_number":"0001390478-23-000025","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Q3 net loss $9.3M; GPS Phase 3 enrollment complete, SLS009 shows CR in AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.3M ($0.33/share) vs $7.0M in Q3 2022; cash $4.0M as of Sep 30, 2023; subsequent $4.0M offering.","Phase 3 REGAL trial of GPS in AML expected to complete enrollment (ex-China) in November 2023; interim data late 2023/early 2024.","SLS009 Phase 2a in AML: first patient achieved complete response, six of seven patients alive; anti-leukemic effects in all.","FDA granted Orphan Drug Designation for SLS009 in AML and Fast Track for r/r PTCL.","Anticipating $13.0M milestone from 3D Medicines upon China enrollment in REGAL in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259513,"accession_number":"0001104659-23-112759","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SELLAS receives FDA Fast Track for SLS009 in PTCL; raises $4M via registered direct offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for SLS009 to treat relapsed/refractory Peripheral T-cell Lymphomas (PTCL).","SLS009 showed 36.4% overall response rate in Phase 1 PTCL patients vs 25.8% for standard of care belinostat.","Registered direct offering of 3,652,300 shares/warrants at $1.0952/share for ~$4M gross proceeds; closing expected Nov 2, 2023.","Existing warrants from April 2022 repriced to $0.9702 and extended to November 2, 2028.","A.G.P./Alliance Global Partners acting as lead placement agent; Maxim Group as co-placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259512,"accession_number":"0001104659-23-109256","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SELLAS reports positive Phase 2a topline data for SLS009 in AML; first patient achieved complete response","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First of 5 enrolled r/r AML patients achieved complete response, remains alive in 5th month of treatment.","All 5 patients alive at last follow-up; 4 continue treatment; anti-leukemic effects seen in all.","No significant safety issues observed at 45 mg dose level; median OS for venetoclax-failure AML is ~2.5 months.","SLS009 is first CDK9 inhibitor to achieve CR in combination with AZA/VEN in venetoclax-resistant AML.","Topline data for 60 mg dose expected later this quarter; multiple registrational opportunities cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259511,"accession_number":"0001104659-23-108983","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SELLAS expects REGAL enrollment ex-China by Nov 2023; China start triggers $13M milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment outside China expected to complete in November 2023; patient numbers for interim and final analyses already enrolled.","Interim analysis (60 events) on track for late 2023/early 2024; final analysis (80 events) targeted by end of 2024.","China partner 3D Medicines to begin REGAL enrollment in Q4 2023, triggering two milestone payments totaling $13.0 million.","3D Medicines has obtained all regulatory permits and set up 11 treatment centers in China; previously projected Q3 start delayed by supply-chain issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276776,"accession_number":"0001390478-23-000020","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS reports Q2 net loss $8.8M; AML trials on track with IDMC meeting Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.8M ($0.31/share) vs $8.4M ($0.41/share) in Q2 2022; cash $13.8M at June 30.","Phase 3 REGAL (GPS) interim analysis expected late 2023/early 2024; IDMC meeting in Q3 2023.","Phase 2a SLS009 in AML dosed; topline data expected Q4 2023; Phase 1 safety completed.","Expects $13M milestone payments from 3D Medicines by end of Q3 2023.","R&D expenses $5.9M (up from $5.5M) driven by GPS and SLS009 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294592,"accession_number":"0001104659-23-073005","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SELLAS Life Sciences re-elects directors, approves equity plan increase, but fails to pass officer exculpation amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert Van Nostrand and Jane Wasman re-elected as Class I directors with ~5.45M and ~5.48M votes for, respectively.","Ratification of Moss Adams LLP as independent auditor for FY2023 approved: 13.5M for, 1.0M against, 0.8M abstain.","Amendment to 2019 Equity Incentive Plan increasing authorized shares by 3 million approved: 4.68M for, 3.27M against.","Proposal to amend certificate of incorporation for officer exculpation failed; required majority of outstanding shares — only 6.04M of 15.30M voted for.","Non-binding advisory vote on executive compensation passed: 4.77M for, 3.08M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294591,"accession_number":"0001104659-23-067033","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SELLAS to begin Phase 2a AML trial of CDK9 inhibitor GFH009; Phase 1 showed complete response in monotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a single-arm trial to enroll up to 20 R/R AML patients previously failed venetoclax/azacitidine; primary endpoints: composite CR rate, duration of response, safety.","Trial expected to open June 2023 with top-line data by end of 2023; GFH009 dosed at 45 or 60 mg weekly in combination with standard aza/ven.","Phase 1 produced the first known complete response (MRD-negative, >6 months) from a CDK9 inhibitor monotherapy in R/R AML; no DLTs observed.","GFH009 targets MCL1 transcription, synergizing with BCL2 inhibitor venetoclax; triple combo may overcome venetoclax resistance by hitting both anti-apoptotic pathways.","GPS Phase 3 REGAL AML IDMC meeting set for Q3 2023; interim analysis expected by year-end 2023 or early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294590,"accession_number":"0001390478-23-000013","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS reports Q1 net loss $11.1M; GFH009 Phase 1 complete in AML, Phase 2a to start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.1M ($0.47/share) vs $16.7M ($1.05/share) in Q1 2022; cash $23.9M at March 31.","Phase 1 of GFH009 in AML completed; 94% of patients alive, durable remission >6 months; Phase 2a starting Q2.","Phase 3 REGAL study of GPS in AML on track for interim analysis late 2023/early 2024; IDMC OK.","3D Medicines to trigger $13M milestone payments by Q3 2023 via REGAL participation in China.","No licensing revenue in Q1 2023 (vs $1M in Q1 2022); R&D expenses rose to $7.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315202,"accession_number":"0001390478-23-000006","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SELLAS Life Sciences reports FY2022 net loss $41.3M; cash $17.1M, raised $20M in Feb 2023 plus $13M milestone expected","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.3M ($2.13 per share) vs $20.7M loss ($1.34 per share) in 2021.","Cash $17.1M at Dec 31, 2022; subsequent $20M public offering gross proceeds in Feb 2023.","Phase 3 REGAL AML study interim analysis expected late 2023/early 2024.","$13M milestone payment from 3D Medicines expected in H1 2023.","Phase 1 of CDK9 inhibitor GFH009 shows no dose-limiting toxicities; first confirmed CR in AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315201,"accession_number":"0001104659-23-031169","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SELLAS says exposure to Silicon Valley Bank closure is immaterial","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["SVB closed by California regulator; FDIC appointed receiver.","SELLAS considers its exposure to any SVB liquidity concern as immaterial.","Company states no material financial impact from SVB shutdown."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315200,"accession_number":"0001104659-23-027009","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SELLAS closes $18.5M offering; reprices 3.4M warrants to $3.62","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten offering of 7,220,217 shares and warrants for net proceeds of ~$18.5M.","Amended 3,438,851 warrants issued April 2022, reducing exercise price from $5.40 to $3.62.","New exercise price equals average closing price over five trading days before offering pricing.","Offering and warrant amendments executed on February 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315199,"accession_number":"0001104659-23-025048","cik":1390478,"company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SELLAS Life Sciences prices $20M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7,220,217 shares and warrants at $2.77/unit; gross proceeds $20M.","Net proceeds ~$18.5M after underwriting discounts and offering expenses.","Warrants exercisable at $2.77/share, immediately exercisable, expire in 5 years.","Company reduces exercise price of 3,438,851 existing warrants to $3.62.","Offering expected to close on February 28, 2023, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1680804323.0227273,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-24T23:59:59+00:00|315199"}